InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,354.54
(
0.03%
)
US TECH 100
18,547.60
(
0.07%
)
Dow Jones
38,945.56
(
0.15%
)
Brent Oil
79.59
(
-0.37%
)
Bitcoin
70,867.86
(
0.15%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119784
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 11407

Thursday, 09/18/2008 3:01:46 AM

Thursday, September 18, 2008 3:01:46 AM

Post# of 19309
How is Novo Nordisk preparing for NovoSeven patent expiration?

[Updated for Neose Technologies liquidation.]


NVO’s blockbuster rFVIIa drug, NovoSeven, goes off-patent in the US—its largest market—in 2011. NVO has a two-pronged approach to deal with this predicament:

1. A fast-acting FVIIa analog called NN1731, which is in phase-2:
http://seloken.com/secNewsItem/Variant-rFVIIa-more-active-than-NovoSeven.aspx . (Note that fast acting is not the same thing as short acting.)

2. A long-acting FVIIa analog called NN7128 based on pegylation technology from Neose Technologies, which has completed phase-1 (#msg-29710045). On 9/17/08, Neose announced a liquidation of the company and the sale of its NN7128 assets to NVO (#msg-32247019).

Clearly, both of these programs warrant close attention by GTC investors. However, these two drug candidates are FVIIa analogs, not FVIIa per se. Thus, they would seem to incur a higher regulatory risk than the FVIIa program from GTC and LFB.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up